Mirati Therapeutics (NASDAQ:MRTX) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

MRTX has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, November 7th. Cann reaffirmed a “buy” rating and set a $18.00 price objective on shares of Mirati Therapeutics in a research report on Monday, January 8th. Cowen started coverage on Mirati Therapeutics in a research report on Thursday, December 21st. They set an “outperform” rating for the company. Leerink Swann raised Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price objective for the company in a research report on Tuesday, November 14th. Finally, Oppenheimer set a $18.00 price objective on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $14.75.

Shares of Mirati Therapeutics (MRTX) opened at $27.10 on Thursday. Mirati Therapeutics has a 1 year low of $2.70 and a 1 year high of $30.50. The firm has a market capitalization of $723.43, a P/E ratio of -8.71 and a beta of 2.17.

In other news, SVP Jamie Christensen sold 14,725 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $22.99, for a total transaction of $338,527.75. Following the completion of the transaction, the senior vice president now directly owns 6,395 shares of the company’s stock, valued at approximately $147,021.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were acquired at an average cost of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 71,314 shares of company stock valued at $1,831,831. Company insiders own 5.10% of the company’s stock.

Several hedge funds have recently modified their holdings of MRTX. Jennison Associates LLC purchased a new position in shares of Mirati Therapeutics during the 4th quarter worth approximately $8,899,000. Broadfin Capital LLC raised its stake in shares of Mirati Therapeutics by 19.1% during the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after buying an additional 400,000 shares in the last quarter. BlackRock Inc. raised its stake in shares of Mirati Therapeutics by 57.5% during the 4th quarter. BlackRock Inc. now owns 510,362 shares of the biotechnology company’s stock worth $9,314,000 after buying an additional 186,419 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Mirati Therapeutics by 68.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock worth $3,939,000 after buying an additional 137,104 shares in the last quarter. Finally, Artal Group S.A. purchased a new position in shares of Mirati Therapeutics during the 4th quarter worth approximately $1,825,000. 66.29% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Mirati Therapeutics (MRTX) Rating Increased to Strong-Buy at BidaskClub” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/mirati-therapeutics-mrtx-rating-increased-to-strong-buy-at-bidaskclub/1857790.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.